Cholesterol, C-reactive protein, and cerebrovascular events following intensive and moderate statin therapy

Journal of Thrombosis and Thrombolysis

Volumn 22, Issue 1, 2006, Pages 71-76

  Mega, Jessica L ^a   Morrow, David A ^b   Cannon, Christopher P ^b   Murphy, Sabina ^d   Cairns, Richard ^c   Ridker, Paul M ^b   Braunwald, Eugene ^b  

^a MASSACHUSETTS GENERAL HOSPITAL   (United States)

^b BRIGHAM AND WOMEN S HOSPITAL   (United States)

^c Nottingham Clinical Research Group   (United Kingdom)

^d MGH Cardiovascular Division ^*

Author keywords

C reactive protein; Cerebrovascular event; Cholesterol; Hydroxymethylglutaryl CoA reductase inhibitors

Indexed keywords

ATORVASTATIN; BIOLOGICAL MARKER; C REACTIVE PROTEIN; CHOLESTEROL; GATIFLOXACIN; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; LOW DENSITY LIPOPROTEIN; PLACEBO; PRAVASTATIN;

ACUTE CORONARY SYNDROME; ACUTE HEART INFARCTION; ADULT; AGED; ARTICLE; BLOOD SAMPLING; CEREBROVASCULAR ACCIDENT; CHOLESTEROL BLOOD LEVEL; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; FEMALE; FOLLOW UP; HIGH RISK PATIENT; HUMAN; LIPOPROTEIN BLOOD LEVEL; MAJOR CLINICAL STUDY; MALE; MULTIVARIATE ANALYSIS; PREDICTOR VARIABLE; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; RANDOMIZED CONTROLLED TRIAL; RISK ASSESSMENT; RISK REDUCTION; TRANSIENT ISCHEMIC ATTACK; TREATMENT OUTCOME; TREATMENT RESPONSE; UNSTABLE ANGINA PECTORIS;

AGED; ANGINA, UNSTABLE; C-REACTIVE PROTEIN; CEREBROVASCULAR ACCIDENT; CHOLESTEROL; EPIDEMIOLOGIC METHODS; FEMALE; FLUOROQUINOLONES; HEPTANOIC ACIDS; HUMANS; HYDROXYMETHYLGLUTARYL-COA REDUCTASE INHIBITORS; MALE; MIDDLE AGED; MYOCARDIAL INFARCTION; PRAVASTATIN; PYRROLES;

EID: 33745278035     PISSN: 09295305     EISSN: None     Source Type: Journal    
DOI: 10.1007/s11239-006-8081-0     Document Type: Article

References (33)

1. Cholesterol, diastolic blood pressure, and stroke: 13,000 strokes in 450,000 people in 45 prospective cohorts (1995) Prospective studies collaboration. Lancet 346:1647-1653
2. Bowman TS, Sesso HD, Ma J, et al (2003) Cholesterol and the risk of ischemic stroke. Stroke 34:2930-2934
3. Iso H, Jacobs DR, Jr., Wentworth D, Neaton JD, Cohen JD (1989) Serum cholesterol levels and six-year mortality from stroke in 350,977 men screened for the multiple risk factor intervention trial. N Engl J Med 320:904-910
4. Yano K, Reed DM, MacLean CJ (1989) Serum cholesterol and hemorrhagic stroke in the Honolulu Heart Program. Stroke 20:1460-1465
5. Randomised trial of cholesterol lowering in 4444 patients with coronary heart disease: The Scandinavian Simvastatin Survival Study (4S) (1994) Lancet 344:1383-1389
6. Plehn JF, Davis BR, Sacks FM, et al (1999) Reduction of stroke incidence after myocardial infarction with pravastatin: The Cholesterol and Recurrent Events (CARE) study. The Care Investigators. Circulation 99:216-223
7. White HD, Simes RJ, Anderson NE, et al (2000) Pravastatin therapy and the risk of stroke. N Engl J Med 343:317-326
8. Byington RP, Davis BR, Plehn JF, et al (2001) Reduction of stroke events with pravastatin: The Prospective Pravastatin Pooling (PPP) Project. Circulation 103:387-392
9. Waters DD, Schwartz GG, Olsson AG, et al (2002) Effects of atorvastatin on stroke in patients with unstable angina or non-Q-wave myocardial infarction: A Myocardial Ischemia Reduction with Aggressive Cholesterol Lowering (MIRACL) substudy. Circulation 106:1690-1695
10. (2002) MRC/BHF Heart Protection Study of cholesterol lowering with simvastatin in 20,536 high-risk individuals: A randomised placebo-controlled trial. Lancet 360:7-22
11. Sever PS, Dahlof B, Poulter NR, et al (2003) Prevention of coronary and stroke events with atorvastatin in hypertensive patients who have average or lower-than-average cholesterol concentrations, in the Anglo-Scandinavian Cardiac Outcomes Trial-Lipid Lowering Arm (ASCOT-LLA): A multicentre randomised controlled trial. Lancet 361:1149-1158
12. Collins R, Armitage J, Parish S, Sleight P, Peto R (2004) Effects of cholesterol-lowering with simvastatin on stroke and other major vascular events in 20536 people with cerebrovascular disease or other high-risk conditions. Lancet 363:757-767
13. Hebert PR, Gaziano JM, Chan KS, Hennekens CH (1997) Cholesterol lowering with statin drugs, risk of stroke, and total mortality. An overview of randomized trials. Jama 278:313-321
14. Blauw GJ, Lagaay AM, Smelt AH, Westendorp RG (1997) Stroke, statins, and cholesterol. A meta-analysis of randomized, placebo-controlled, double-blind trials with HMG-CoA reductase inhibitors. Stroke 28:946-950
15. Crouse JR, 3rd, Byington RP, Furberg CD (1998) HMG-CoA reductase inhibitor therapy and stroke risk reduction: An analysis of clinical trials data. Atherosclerosis 138:11-24
16. Bucher HC, Griffith LE, Guyatt GH (1998) Effect of HMGcoA reductase inhibitors on stroke. A meta-analysis of randomized, controlled trials. Ann Intern Med 128:89-95
17. Law MR, Wald NJ, Rudnicka AR (2003) Quantifying effect of statins on low density lipoprotein cholesterol, ischaemic heart disease, and stroke: Systematic review and meta-analysis. Bmj 326:1423
18. Liao JK (2002) Statins and ischemic stroke. Atheroscler Suppl 3:21-25
19. Ridker PM, Rifai N, Pfeffer MA, Sacks F, Braunwald E (1999) Long-term effects of pravastatin on plasma concentration of C-reactive protein. The Cholesterol and Recurrent Events (CARE) Investigators. Circulation 100:230-235
20. Albert MA, Danielson E, Rifai N, Ridker PM (2001) Effect of statin therapy on C-reactive protein levels: The pravastatin inflammation/CRP evaluation (PRINCE): A randomized trial and cohort study. Jama 286:64-70
21. Ridker PM, Cushman M, Stampfer MJ, Tracy RP, Hennekens CH (1997) Inflammation, aspirin, and the risk of cardiovascular disease in apparently healthy men. N Engl J Med 336:973-979
22. Gussekloo J, Schaap MC, Frolich M, Blauw GJ, Westendorp RG (2000) C-reactive protein is a strong but nonspecific risk factor of fatal stroke in elderly persons. Arterioscler Thromb Vasc Biol 20:1047-1051
23. Ford ES, Giles WH (2000) Serum C-reactive protein and self-reported stroke: Findings from the Third National Health and Nutrition Examination Survey. Arterioscler Thromb Vasc Biol 20:1052-1056
24. Rost NS, Wolf PA, Kase CS, et al (2001) Plasma concentration of C-reactive protein and risk of ischemic stroke and transient ischemic attack: The Framingham study. Stroke 32:2575-2579
25. Tirschwell DL, Smith NL, Heckbert SR, Lemaitre RN, Longstreth WT, Jr., Psaty BM (2004) Association of cholesterol with stroke risk varies in stroke subtypes and patient subgroups. Neurology 63:1868-1875
26. Milionis HJ, Rizos E, Goudevenos J, Seferiadis K, Mikhailidis DP, Elisaf MS (2005) Components of the metabolic syndrome and risk for first-ever acute ischemic nonembolic stroke in elderly subjects. Stroke 36:1372-1376
27. Cannon CP, Braunwald E, McCabe CH, et al (2004) Intensive versus moderate lipid lowering with statins after acute coronary syndromes. N Engl J Med 350:1495-1504
28. Nissen SE, Tuzcu EM, Schoenhagen P, et al (2004) Effect of intensive compared with moderate lipid-lowering therapy on progression of coronary atherosclerosis: A randomized controlled trial. Jama 291:1071-1080
29. Ridker PM, Cannon CP, Morrow D, et al (2005) C-reactive protein levels and outcomes after statin therapy. N Engl J Med 352:20-28
30. Nissen SE, Tuzcu EM, Schoenhagen P, et al (2005) Statin therapy, LDL cholesterol, C-reactive protein, and coronary artery disease. N Engl J Med 352:29-38
31. Amarenco P, Bogousslavsky J, Callahan AS, et al (2003) Design and baseline characteristics of the stroke prevention by aggressive reduction in cholesterol levels (SPARCL) study. Cerebrovasc Dis 16:389-395
32. LaRosa JC, Grundy SM, Waters DD, et al (2005) Intensive lipid lowering with atorvastatin in patients with stable coronary disease. N Engl J Med 352:1425-1435
33. de Lemos JA, Blazing MA, Wiviott SD, et al (2004) Early intensive vs a delayed conservative simvastatin strategy in patients with acute coronary syndromes: Phase Z of the A to Z trial. Jama 292:1307-1316